New Zealand Cosmetic Regulations Explained

Quick Answer: New Zealand cosmetic regulation starts with product classification, then the rules that apply to its composition and supply. EPA administers the Cosmetic Products Group Standard, while Medsafe explains the medicines boundary. The revised cosmetic rules took effect on 1 January 2026, with separate later transitions for general non-compliance, PFAS and certain homosalate products. Review each product’s actual formula and claims against the current framework.

MOOYAM editorial content. Last reviewed: 14 October 2026. Cover: AI-generated editorial illustration.

Understand the framework before asking for a certificate

A cosmetic brand needs a map of the rules that apply to its product, rather than a folder of certificates with uncertain relevance. Start by defining the composition, purpose, claims and supply activities. These facts determine which questions need review. The same cream format can appear in different regulatory contexts when its ingredients or advertised purpose change.

The Medsafe categorisation guidance addresses the boundary between cosmetics and therapeutic products. The EPA current cosmetic rules guidance explains changes to the hazardous-substances framework for cosmetics. These sources answer different questions. A formulation review cannot, by itself, settle every implication of a therapeutic advertising claim.

For the operational steps from assessment to shipment, use a neighbouring-market launch planning guide. For a deeper discussion of the supplier inputs needed for composition screening, read an example of ingredient evidence planning for Australia.

EPA: the cosmetic group-standard workstream

EPA says the revised Cosmetic Products Group Standard 2020 became effective on 1 January 2026. The widened scope includes finished cosmetics that are non-hazardous but contain a hazardous ingredient. Brands should therefore avoid treating a finished-product hazard summary as the complete test of whether the standard applies.

The changes include updated ingredient schedules, PFAS phase-out arrangements and nanomaterial records. EPA’s guidance also notes an extension affecting products containing more than 10% homosalate. The detailed legal conditions belong in the current group standard. A public overview is helpful for orientation, but it should not be substituted for a formula-specific legal review.

In an evidence file, distinguish scope assessment from ingredient assessment. Record why the product is within the relevant framework, then record how its composition and other applicable conditions were assessed. If the scope conclusion changes after a supplier reveals additional composition information, reconsider the downstream conclusions as well.

Medsafe: composition, purpose and presentation

Medsafe describes categorisation as a combined assessment of ingredients, intended use and market presentation. Its guidance says cosmetics cannot contain ingredients scheduled as controlled drugs or the specified medicine categories. It also states that therapeutic claims are not permitted for products supplied as cosmetics. These points make category review a prerequisite to treating a product as an ordinary cosmetic.

Presentation extends beyond a carton. Medsafe includes websites, advertising context, testimonials and influencer material among the ways intended purpose can be conveyed. Give the reviewer the real commercial materials, including content created by distributors. If the website describes a disease-treatment purpose while the pack contains only beauty wording, the pack alone is an incomplete picture.

Certain product exclusions have conditions, and should not be generalised from a familiar product type. For example, a brand should not assume every anti-acne or antibacterial presentation belongs in the same category. Ask for an assessment of the precise formula, concentration, claims and context. Retain that assessment with the approved commercial materials.

Keep the transition dates separate

The dates below summarise EPA’s published guidance reviewed on 14 October 2026. They describe different transition categories. Before relying on a date for an individual stock line, confirm that the product qualifies for the relevant transitional arrangement and check the legal instrument. A later deadline for one ingredient category is not a blanket extension for all compliance requirements.

General rule changes and the PFAS transition follow different schedules. Homosalate products above the specified threshold have their own dates. A brand operating several product families should therefore maintain SKU-level decisions rather than a single spreadsheet field labelled “New Zealand deadline.”

Use this distinction in inventory and purchasing conversations. Identify stock already held, goods planned for import and formulas still under development. Assign each to its reviewed category. A production booking made before a transition date does not automatically determine whether a later import or sale is permitted.

Build a responsibility matrix that matches the supply route

Write down who imports, manufactures, supplies and retails the product. Include the overseas manufacturer, brand owner, local importing business, distributor and retailer as applicable. Then identify the party handling each review and record. The commercial contract should make information handover practical, without assuming that a contract clause can redefine a statutory obligation.

A technical team needs access to composition data; an artwork team needs the approved directions and declarations; the local business needs the applicable conclusions and deadlines. Connect these people through a named project owner. When the supplier changes a raw material, that owner should know who must review the change before commercial release.

Use a private label manufacturing brief to document what the supplier can provide. Ask for precise descriptions of available reports and specifications. Avoid presenting a general manufacturing statement as a New Zealand regulator’s approval or as evidence that every retail claim has been accepted.

Choose evidence for the question it answers

Each document should have an identifiable role. A raw-material SDS informs hazard and handling questions. A COA links specified attributes to a material or batch. A stability report concerns the tested conditions and product version. An ingredient statement helps with identity and declaration review. None should be described as answering unrelated questions that were never assessed.

Keep a document register with formula version, issuer, date, relevant batch or sample and reviewer use. If a report belongs to a predecessor formula, flag that limitation. Ask whether the changed composition or packaging affects the conclusion. Do not simply attach an older report to a new product because the marketing name stayed the same.

For a retailer handover, prepare a concise approved summary that points back to the underlying records. It should identify what was reviewed and what remains conditional. This supports commercial conversations without circulating proprietary formula data unnecessarily or implying the retailer received a government-issued clearance.

Monitor changes after the product is launched

A current review is a snapshot of a defined product and presentation. Keep a change log for formula, raw materials, claims, suppliers, packaging and distribution arrangements. Assign review triggers so apparently small changes do not bypass the process. A preservative substitution and a new therapeutic testimonial may require different reviewers, but both need a deliberate decision.

Schedule periodic checks of the official sources used in the assessment. The purpose is to identify a change that affects the product, not to manufacture a new compliance claim every time a webpage is updated. Record the source version and the reason a new review was or was not necessary. This keeps the history understandable to a later project team.

MOOYAM can discuss formulation, packaging and available manufacturing evidence for a defined OEM/ODM project. Share the local reviewer’s requests through the project enquiry page. The responsible New Zealand parties should own the local decisions, including whether a revised formula or commercial claim can be released.

Frequently asked questions

What changed in New Zealand cosmetic rules in 2026?

EPA’s revised group standard took effect on 1 January 2026. Its guidance identifies expanded scope, updated ingredient schedules, nanomaterial record changes and phased ingredient restrictions.

Do EPA and Medsafe perform the same role?

No. EPA’s cosmetic group-standard guidance addresses the hazardous-substances framework. Medsafe’s categorisation guidance addresses whether composition, purpose and presentation place a product at the therapeutic boundary.

Are all phase-out dates 1 January 2027?

No. EPA publishes separate import/manufacture, sale and disposal dates, including distinct PFAS and homosalate transitions. Assess the product’s category before applying a deadline.

Does a non-hazardous finished formula fall outside the standard?

Not automatically. EPA says the expanded scope includes a non-hazardous cosmetic containing a hazardous ingredient. The actual composition must be considered.

Can a brand rely on an old overseas compliance file?

Use it as supporting material, then check its relevance to the current New Zealand framework, actual formula and final claims. Record the market-specific conclusion rather than assuming equivalence.